16 October 2024
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Issue of Equity and Total
Voting Rights
SkinBioTherapeutics plc, (AIM: SBTX,
or the "Company"), the life science business focused on skin
health, announces that it has issued, conditional on admission,
2,349,624 new ordinary shares of 1 pence each in the capital of the
Company ("Ordinary Shares"), pursuant to the subscription agreement
entered into by the Company and an existing shareholder announced
on 11 October 2024.
The new Ordinary Shares will rank
pari passu with the existing Ordinary Shares in issue and
application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the
new Ordinary Shares commence, at 8:00 a.m. on 17 October
2024.
Total Voting Rights
Following Admission, the Company
will have 228,435,909 Ordinary Shares in issue. This figure of
228,435,909 may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
-Ends-
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
Tel: +44 (0) 191 495 7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
Tel: +44 (0) 20 7220 0500
|
|
Vigo
Consulting (financial press)
Rozi Morris
|
+44 (0) 20 7390 0231
+44 (0) 7740 859 962
Skinbio@vigoconsulting.com
|
|
|
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the
University of Manchester.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com
and www.axisbiotix.com.
